SDC1 and Miyoshi myopathy: In this sense, the prominent role of CD138 in MM biology suggests the identification and development of novel therapeutic agents to suppress its activity, as no CD138-targeted therapy has yet been approved for clinical use in MM and only few are being investigated in relevant clinical phases.